Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
Some patients experience noticeable effects from small dose changes
Product Specifications Laboratory Handling Store lyophilised vials at -20C, sealed and protected from light
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has warned that drugs in the glucagon-like peptide-1 (GLP-1) class, such as Wegovy, used to treat diabetes and obesity, could potentially cause severe acute pancreatitis
Dont Have Diabetes Diagnosis The Problem: Mounjaro only covered for type 2 diabetes Want tirzepatide for weight loss only Dont qualify for Mounjaro coverage Zepbound not covered either The Solution: Alternatives dont require diabetes diagnosis and focus on weight loss indication
Aulinger BA, Bedorf A, Kutscherauer G et al (2014) Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade
US$ 21.92
US$ 29.96
US$ 29.73
US$ 23.96
US$ 28.08
US$ 23.80
US$ 29.95
US$ 28.81
